U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FRISCO, Texas, Jan. 19, 2017 -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, today announced that its subsidiary, Centro de Construccion de Cardioestimuladores del Uruguay S.A. (CCC), has signed a new supply agreement with Mainstay Medical Limited (MML), a subsidiary of Mainstay Medical International plc (Mainstay).
|
|||
The supply agreement becomes effective in January 2017 and replaces the engineering agreement that has been in place since 2010. Under the supply agreement, CCC will continue as the exclusive manufacturer of the implantable pulse generator and certain accompanying technology, including software, for MML’s ReActiv8® system. ReActiv8 is an implantable neurostimulation system used to treat disabling Chronic Low Back Pain (CLBP).
“Our agreement with Mainstay further demonstrates Integer’s growing position as a key service provider in the development and manufacturing of integrated systems within the active implantable market,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management & Neuromodulation product category. “We are excited to extend our partnership with Mainstay and we look forward to our continued role in helping Mainstay bring ReActiv8 to market. Through their relationship with us, Mainstay is able to leverage our core technology and manufacturing footprint to more efficiently and cost-effectively bring the ReActiv8 system to patients suffering from CLBP.”
Peter Crosby, Mainstay’s CEO, said, “We are pleased to complete the new supply agreement with CCC as we advance our commercialization activities relating to ReActiv8.”
About Integer™
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include GreatbatchTM Medical, Lake Region MedicalTM and ElectrochemTM. Additional information is available at www.integer.net.
Integer Contacts Investor Relations Amy Wakeham [email protected] 214.618.4978 Media Relations Jeannine Lee [email protected] 972.668.4593
